- Open Access
Blockade of the amino acid transporter SLC6A14 suppresses tumor growth in colorectal Cancer
BMC Cancer volume 22, Article number: 833 (2022)
The amino acid transporter SLC6A14, which transports 18 of the 20 proteinogenic amino acids, is too low to be detected in healthy normal tissues but is significantly increased in some solid cancers. However, little is known about the roles of SLC6A14 in colorectal cancer (CRC).
The mRNA and protein levels of SLC6A14 were detected using TCGA database, real-time polymerase chain reaction, western blot, and tissue microarrays, respectively. Amino acids concentration was determined by LC-MS/MS. Cell proliferation and apoptosis were determined using MTT assay and flow cytometry. Transwell invasion assay and wound healing assay were employed to analyze cell migration and invasion. The protein levels of Akt-mTOR signaling pathway and MMPs proteins were detected by western blot.
Both of the mRNA and protein levels of SLC6A14 were upregulated in CRC tissues, and the protein levels of SLC6A14 were closely related to the tumor cells differentiation: the higher the expression of SLC6A14 was, the poorer the differentiation of the tumor cells was. Further knockdown SLC6A14 with siRNA or treatment with α-MT in CRC cell lines reduced cell proliferation and migration in vitro and inhibited xenograft tumor growth in vivo. Mechanistically, SLC6A14 was demonstrated to regulate the expression and phosphorylation of Akt-mTOR, which mediates the promoting tumor growth function of SLC6A14. Blockade of SLC6A14 with α-MT inhibited the activation of mTOR signaling.
SLC6A14 was upregulated in CRC and could promote tumor progression by activating the Akt-mTOR signaling pathway, which may serve as an effective molecular target for the treatment of CRC.
Colorectal cancer (CRC) is the fourth cancer leading cause of death worldwide, and the morbidity and mortality rates have increased in recent years . Up to now, the treatment of CRC is still based on early detection and surgical resection, while the treatment strategies for recurrence and metastasis of CRC patients are still limited. Moreover, targeted drugs are only effective in less than 20% of metastatic colorectal cancers [2, 3]. Therefore, it is important to find new targets for targeted therapy for CRC. Nowadays, gene microarrays, protein microarrays, and tumor metabonomics are all important means for identification of tumor markers, serodiagnosis, and new targeted therapies [4, 5].
Rapid proliferation of cancer cells increases the requirement for nutrients. Amino acids are essential for protein and nucleotide synthesis. However, mammalian cells cannot synthesize essential amino acids and need specific transporters to obtain them from the extracellular medium via the plasma membrane . The expression of many different amino acid transporters is upregulated on the surface of tumor cells based on their molecular signature and metabolic profile to support increased biosynthesis [7, 8]. Recent interests have focused on amino acid transport and utilization in the field of tumor cell metabolism : SLC1A5, alanine/serine/cysteine transporter 2, is upregulated in various cancers [10, 11]; SLC7A5, high affinity transporter of many neutral amino acids, is significantly upregulated in pancreatic cancer and hepatocellular carcinoma ; SLC7A11 mediates the influx of cystine, accompanied by the efflux of glutamate, and its upregulation protects cancer cells from oxidative stress [13, 14]. Moreover, the upregulation of SLC7A11 is often caused by deletion or inactivation of p53 . Our previous studies have shown that the arginine transporter SLC7A1 is overexpressed in colorectal cancer tissues and is associated with cell growth .
SLC6A14/ATB0,+ transports all neutral amino acids and the two cationic amino acids, a total of 18 proteinogenic amino acids. Three different driving forces are involved in the activation of this transporter: a Na+ gradient, a Cl− gradient, and a membrane potential. The stoichiometric ratio of Na+/Cl −/amino acid is 2:1:1, because its transport function is coupled with Na+ and Cl− . Due to its broad substrate selectivity, SLC6A14 is an ideal transporter to meet the increased needs for amino acids in cancer cells . SLC6A14 expression is too low to be detected in healthy tissues but is significantly increased in pancreatic, cervical, and breast cancers [19,20,21]. SLC6A14 knockout mice showed a low tumor incidence with normal fertility and mammary gland development. Moreover, many immunoglobulin genes were upregulated in SLC6A14−/− mice, suggesting that the antitumor immune response might be stimulated . Molecular characterization of SLC6A14 in transgenic models of breast cancer showed that CCAAT-enhancer binding protein homologous protein and asparagine synthetase were upregulated and might be responsible for the poor growth of tumors. α-Methyltryptophan (α-MT) has been identified as a pharmacologic blocker for SLC6A14 with minimal toxicity . All these functions of SLC6A14 indicate that it deserves more attention as a new and effective method to target the anabolism of cancer cells. Although the upregulation of SLC6A14 was reported in CRC, because of the small sample size, the roles of SLC6A14 in CRC, the relationship between SLC6A14 and the clinicopathological characteristics of CRC and the underlying mechanisms were not fully understood [24, 25].
Therefore, we investigated the role of SLC6A14 in the pathogenesis of CRC and detected its clinicopathological correlation through four hundred and eighty-two tissue samples in this study. We found the effects of SLC6A14 on tumor cell growth in vitro and tumorigenesis in vivo, and confirmed that Akt-mTOR signaling was activated in SLC6A14-mediated CRC progression. Furthermore, we identified α-MT as an effective inhibitor targeting SLC6A14 to suppress tumor growth in CRC.
Patient samples and ethical approval
Four hundred and eighty-two tissue samples and twenty-eight pairs of human colorectal cancer and adjacent normal tissues were obtained from patients who underwent surgery at Shanghai East Hospital of Tongji University. All included patients met the following inclusion criteria: (1) pathological diagnoses were confirmed; (2) no preoperative chemotherapy or radiotherapy; (3) complete clinical data; and (4) informed consent was obtained. Exclusion criteria: (1) Patients with other primary tumors; (2) CRC recurrence patients with a second operation; (3) Follow-up data were missing. Normal tissues that were at least 5 cm away from the tumor were obtained from the patients. CRC specimens were staged in accordance with the 2010 American Joint Committee on Cancer staging system. The whole study was approved by the Ethics Committee of Shanghai East Hospital (No. 2018051).
Cell lines and reagents
Human colorectal cancer cell lines (HT29, SW480, SW620, HCT116, and Caco2), and human liver cancer cell line Huh7 were provided by the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). All cell lines were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal calf serum (FBS) and incubated in a humidified chamber with 5% CO2 at 37 °C. The seeding densities of Caco2 cells were no more than 1 × 106/mL. All experiments were performed using Caco2 cultured < 10 days post-seeding and the cell densities < 80%. DMEM and FBS were purchased from ThermoFisher Scientific, MA, USA. α-MT was purchased from Sigma-Aldrich, MO, USA.
RNA extraction and real-time PCR
Tissue samples were lysed with TRIzol™ (ThermoFisher Scientific, MA, USA) and total RNA was extracted. Reverse transcription was performed using the first-strand cDNA Synthesis Kit (TaKaRa, Kyoto, Janpan) according to the manufacturer’s instructions. Real-time polymerase chain reaction (real-time PCR) was performed using SYBR Premix Ex Taq II PCR (TaKaRa, Kyoto, Japan) on ABI Q6 (Applied Biosystems, CA, USA) according to the manufacturer’s instructions. The sequences of the primers are shown in Supplementary Table 1.
Tissue microarrays and immunohistochemical analysis
Four hundred and eighty-two tissue samples were obtained and used to generate tissue microarrays. The tissue sections were treated with immunohistochemical staining. Sections were heated in the Dako Target Retrieval Solution (Dako, Copenhagen, Denmark) at 95 °C for 20 minutes. After blocking with 3% H2O2, the sections were incubated with the primary antibody (SLC6A14, Abcam, ab254786, rabbit) at 4 °C overnight. They were rinsed with phosphate-buffered saline (PBS) three times for 15 minutes each time and then incubated with the secondary antibody (mouse anti-rabbit IgG-HRP, Santa Cruz, sc-2357) at room temperature for 30 minutes. Finally, the sections were visualized by using the diaminobenzidine (DAB) substrate kit according to the manufacturer’s instructions. The results were scanned on a Pannoraminc viewer (3D HISTECH, Pannoramic MIDI) with Quant Center software. The histochemistry score (H-score) was calculated as follows: H-score = (percentage of cells of weak intensity × 1) + (percentage of cells of moderate intensity × 2) + (percentage of cells of strong intensity × 3) .
SLC6A14 knockdown in CRC cell lines
To knock down SLC6A14 expression in CRC cell lines, we used two siRNA targeted to knockdown SLC6A14 (si-SLC6A14–981: sense 5′-GCAACUCUGGAGGGUGCUUTT-3′, antisense 5′-AAGCACCCUCCAGAGUUGCTT-3′; si-SLC6A14–1702:sense 5′-GGUGGAGAGCUUGCUGGUUTT-3′, antisense 5′-AACCAGCAAGCUCUCCACCTT-3′), and a nonsilencing (NC)-siRNA (GenePharma, Shanghai, China) as a control in HCT116 and Caco2 cell lines. SLC6A14-siRNA or NC-siRNA was transfected into HCT116 and Caco2 cells using Lipofectamine 2000 Reagent (ThermoFisher Scientific, 11,668–019) according to the manufacturer’s instructions. Forty-eight hours after transfection, HCT116 and Caco2 cells were used to determine their function.
Tumorigenicity in vivo
BALB/c nude mice were divided into two groups: the control group was given sucrose-water (5%), and the experimental group was given 2 mg/ml of α-MT in sucrose-water for free drinking starting from 7 days prior to cancer cell injection [20, 21, 27]. In consistence with literature , DL-form of α-MT was used. Both groups of mice were subcutaneously injected with HCT116 cells (1 × 106/mouse) in 100 μl of physiological saline (0.9% NaCl). In the whole process of the experiment, mice in the treatment group were given 2 mg/ml α-MT in sucrose-water continuously and the control group were given sucrose-water only. Tumor volumes were measured and calculated according to the following formula: (length x width2)/2. The width and length of the tumors in each group were measured with vernier caliper once every 3 days. At the end of each experiment, the animals were sacrificed by cervical dislocation and the tumors were isolated and weighted.
All experimental procedures were conducted in accordance with the Public Health Service Policy and complied with the ARRIVE guidelines for the humane use and care of animals. The Institutional Animal Care and Use Committee in Shanghai East Hospital of Tongji University approved the animal experiments reported in the present study (No.2019085).
Western blot analysis
HCT116 or Caco2 cells transfected with siRNA or treated with 2.5 mM α-MT for 48 h were lysed by using RIPA buffer, and the total protein concentration was quantified by BCA assays (Beyotime, Inc., Shanghai, China). The lysates were separated by electrophoresis on a 10% or 8% SDS-PAGE gel and transferred onto a polyvinylidene fluoride (PVDF) membrane. The membranes were blocked with 5% milk (w/v) at room temperature for 1 h, cut into appropriate pieces according to molecular weight or full membranes and then incubated with specific primary antibodies at 4 °C overnight with gentle shaking. We used β-actin (1:1000, Santa Cruz, sc-8432, rabbit) as the loading control. After washed with PBST buffer three times, the membranes were then incubated with secondary antibodies (1:2000, mouse anti-rabbit IgG, Santa Cruz, sc-516,253) at room temperature for another 1 h. The bands of the proteins were visualized using the Odyssey Infrared Imaging System (Li-COR, USA). ImageJ software (National Institutes of Health, Bethesda, MD, USA) was used to perform all densitometric analyses of the bands. The antibodies used in this study included SLC6A14 (1:2000, Abcam, ab254786, rabbit), mTOR (1:1000, CST, 2983S, rabbit), phospho-mTOR (Ser2448) (1:1000, CST, 5536 T, rabbit), GβL (1:1000, CST, 3274 T, rabbit), raptor (1:1000, CST, 2114 T, rabbit), MMP-2 (1:1000, CST, 87809, rabbit), MMP-9 (1:1000, CST, 13667, rabbit), MT1-MMP (1:1000, CST, 13130S, rabbit), Phospho-p70s6 Kinase (1:1000, CST, 9204S, rabbit), Phospho-S6 Ribosomal Protein (1:1000, CST, 4858 T, rabbit), Phospho-4E-BP1 (1:1000, CST, 9456S, rabbit), Akt (1:1000, CST, 4685S, rabbit) and Phospho-Akt (Ser473) (1:1000, CST, 4060S, rabbit).
Detection of amino acids by LC-MS/MS
Amino acids concentration in the culture supernatant of HCT116 cells was determined by LC-MS/MS. Briefly, HCT116 cells transfected with siRNA or pharmacological blockade with 2.5 mM α-MT were plated at 5 × 106 cells/well in 6-well plates and cultured for 24 h. Collect the supernatant and inject it on an Agilent HILIC Plus RRHD column (Agilent, CA, USA) with 5 μl. The flow rate was held constant at 400 μl/min and amino acids were detected.
Cell proliferation assays
MTT assay was performed to determine cell proliferation. Briefly, HCT116 or Caco2 cells transfected with siRNA and cultured in DMEM containing 2.5 mM α-MT were plated at 1 × 103 cells/well in 96-well plates. At the end of each period, the CellTiter 96 Aqueous One Solution Cell Proliferation Assay Kit (Promega, WI, USA) was used according to the manufacturer’s instructions and incubated with HCT116 or Caco2 cells for 4 h at 37 °C. Then the optical density (OD) value was read at the wavelength of 570 nm on an automated plate reader.
Flow cytometry analysis of the cell cycle and apoptosis
Flow cytometry was used to analyze the cell cycle and apoptosis. After collecting HCT116 or Caco2 cells transfected with siRNA or treated with 2.5 mM α-MT, a total of 1 × 106 cells were fixed with 70% ice-cold ethanol for 24 h at 4 °C for cell cycle analysis. The cells were stained with 50 μg/ml propidium iodide containing 0.1 mg/ml RNase A at 37 °C for 15 minutes. The DNA content of the HCT116 or Caco2 cells was determined by BD FACSCalibur cytometry and analyzed by ModFit LT software (Verity Software House, ME, USA). HCT116 or Caco2 cells transfected with siRNA or treated with 2.5 mM α-MT were cultured in FBS-free media for 24 h to induce apoptosis. For the apoptosis analysis, HCT116 or Caco2 cells were collected and stained with Annexin V-FITC and PI Apoptosis Detection Kit (BD Bioscience, NJ, USA).
Cell invasion assay
Cell invasion was measured by using Corning® BioCoat™ Matrigel® Invasion assay kit (Corning, NY, USA) according to the manufacturer’s instructions. HCT116 or Caco2 cells with 4×105 cells/well transfected with siRNA or treated with 2.5 mM α-MT were seeded into the upper chambers in FBS-free media and incubated for 24 h, accompanied by DMEM containing 10% FBS was added to the bottom chambers. Invaded cells on the bottom surface were fixed, stained with 0.5% crystal violet, and counted in five randomly chosen visual fields.
Wound healing assay
When HCT116 or Caco2 cells transfected with siRNA or treated with 2.5 mM α-MT were cultured to about 80% confluence in a 6-well plate, a wound about 800 μm width was created by scratching cells with a sterile 10 μl plastic tip. Cells were cultured with DMEM containing 0.5% FBS for 48 h and photographed.
The quantitative data were shown as mean ± SD. Statistical differences between two groups were analyzed by two-tailed Student’s t-tests, and comparisons among three or more groups by one-way ANOVA, performed with the statistical software SPSS 17.0 (IBM Corporation, NY, USA). Only a p value of less than 0.05 was considered statistically significant.
Identification of SLC6A14 as a potential target in CRC
To determine the amino acid transporter expression profile in colon adenocarcinoma (COAD), we used the publicly available web tool UALCAN (website: http://ualcan.path.uab.edu/index.html)  with The Cancer Genome Atlas (TCGA) database to analyze the expression of common amino acid transporters (including SLC6A14, SLC3 and SLC7 families) in CRC and normal colonic tissue samples. Among the multiple amino acid transporters that exist in COAD, SLC3A2, SLC6A14, SLC7A1, SLC7A6, SLC7A8 and SLC7A11 have been shown to be upregulated (Fig. 1A). Nevertheless, SLC3A1, SLC7A2, SLC7A3, SLC7A4, and SLC7A14 were downregulated (Supplementary Fig. 1 ). There was no significant difference in SLC7A7, SLC7A9, SLC7A10, and SLC7A13 in COAD (data not shown).
Next, we examined SLC6A14, SLC3 and SLC7 families mRNA expression in 28 paired CRC patient tissues by RT-PCR. The results showed that SLC6A14 expression was significantly higher in the cancer tissues than in the paired adjacent normal colon tissues (Fig. 1B). Consistent with the RT-PCR results, the protein expression of SLC6A14 in the CRC tissues was higher than that in the paired adjacent normal colon tissues, as shown in Fig. 1C and D. Furthermore, we found that SLC6A14 expression was substantially increased in the CRC cell lines (HT29, HCT116, SW620 and Caco2) compared to the liver cancer cell line (Huh7) (Fig. 1E).
SLC6A14 was frequently upregulated in CRC and predicted poor differentiation
To further explore the clinicopathological role of SLC6A14 in CRC progression, we assessed the protein expression of SLC6A14 in CRC tissue microarrays using immunohistochemistry staining. In the 482 cases, 302 CRC tissues showed higher SLC6A14 expression compared with the tissues from normal mucosa, adenoma, and liver cancer (Fig. 2A and B). Furthermore, as shown in Table 1, SLC6A14 expression was closely correlated with tumor differentiation: its expression in poorly differentiated tumor tissues was significantly higher than that in moderately and well-differentiated cancer tissues (P < 0.001, Fig. 2C and D). We also observed the positive correlation between SLC6A14 expression and clinical staging: the expression of SLC6A14 in stages III and IV was significantly higher than that in stages I and II (P < 0.001). However, there was no significant correlation among SLC6A14 expression and age, gender, tumor size or tumor location in our analysis.
SLC6A14 promotes CRC cell growth and inhibits apoptosis by transporting amino acids
To determine the biological function of SLC6A14 in CRC, we performed cell proliferation assays, cell apoptosis assays, and cell cycle analysis of HCT116 and Caco2 cells with high SLC6A14 expression. α-Methyltryptophan (α-MT) is an inhibitor of SLC6A14. Western blot analysis showed that the protein expression of SLC6A14 in HCT116 or Caco2 cells after knocking down of SLC6A14 with siRNA was significantly decreased (Fig. 3A and B). LC-MS/MS was used to determine 20 amino acids concentration in the culture supernatant of HCT116 cells and found that 16 amino acids (except L-histidine, L-ornithine, L-citrulline, and L-aspartic acid) concentrations were increased in the culture supernatant of HCT116 cells by silencing SLC6A14 with siRNA or pharmacological blockade of SLC6A14 with α-MT, indicating that SLC6A14 plays an important role in amino acid uptake in the SLC6A14-positive cancer cells (Table 2).
The MTT assay was used to assess cell growth after knockdown SLC6A14 or pharmacological blockade of SLC6A14 with α-MT. As shown in Fig. 3C, the HCT116 or Caco2 cells transfected with SLC6A14-siRNA or blockade with α-MT displayed significant growth inhibition compared with those transfected with NC-siRNA. We also measured cell cycle progression by flow cytometry analysis and found that HCT116 or Caco2 cells transfected with SLC6A14-siRNA or treated with α-MT showed a significant increase in G0/G1 phase and a significant decrease in the S phase compared with those transfected with NC-siRNA (Fig. 4A and B). Whether SLC6A14 affects cell apoptosis was also performed in FBS-free medium or medium with 10% FBS by flow cytometry analysis. Interestingly, the percent of early apoptotic cells significantly increased in the SLC6A14-siRNA-treated or blockade with α-MT cells compared with the NC-siRNA-treated cells (Fig. 4C and D; Supplementary Fig. 3 ). However, the SW480 cells with low SLC6A14 expression treated with either SLC6A14-siRNA or α-MT blockade did not show any significant change of cell proliferation and cell apoptosis, compared with controls as shown in Supplementary Fig. 2 . These findings indicated that SLC6A14 promoted cell proliferation and viability in SLC6A14-positive CRC.
SLC6A14 enhances the migration of CRC cells in vitro
To determine whether SLC6A14 plays a role in cell migration, we performed transwell assays and wound healing assays of HCT116 and Caco2 cells. Transwell assays data demonstrated that SLC6A14 knockdown significantly reduced cell invasion in both the HCT116 and Caco2 cells compared with the NC-siRNA-treated cells (Fig. 5A and B). Consistently, pharmacological blockade of SLC6A14 with α-MT achieved similar effects (Fig. 5A and B). Furthermore, a wound healing assay was employed to detect the effect of SLC6A14 on cell migration. As shown in Fig. 5C and D, knockdown or blockade of SLC6A14 restrained cell motility in the HCT116 and Caco2 cells. These results indicated that SLC6A14 plays an important role in CRC cell migration in vitro.
SLC6A14 regulates the activities of the Akt-mTOR signaling pathway and MMPs
To determine the signaling pathway related to the regulation of CRC cell growth mediated by SLC6A14, several Cell Signaling Technology Pathway Antibody Sampler Kits (CST, MA, USA) were used to compare the activities of common cancer-related cell signaling pathways between the SLC6A14 knockdown and control cells, including the p38/MAPK signaling pathway, Notch activated signaling pathway, mTOR signaling pathway, and matrix remodeling. mTOR signaling activities were found to be affected significantly. As shown in Fig. 6A and B, the expression of total mTOR, phosphorylated mTOR (Ser2448), GβL, and Raptor was downregulated in the SLC6A14 knockdown cells or treatment with α-MT compared to the control HCT116 or Caco2 cells. mTOR, GβL, and Raptor constitute an important signaling pathway in the regulation of tumor growth [29, 30]. Furthermore, downstream effectors of mTOR were investigated by western blot. As shown in Fig. 6D and E, phosphorylation levels of p70S6 and S6 were downregulated in the SLC6A14 knockdown cells or treatment with α-MT compared to the control HCT116 or Caco2 cells, but phosphorylation of 4E-BP1 was upregulated. As the mTOR signaling pathway is usually regulated by PI3K/Akt, the protein levels of total Akt and phosphorylated Akt were examined in HCT116 and Caco2 cells. As shown in Fig. 6 F and G, p-Akt (Ser473) was downregulated in the cells treated with either SLC6A14-siRNA or α-MT, while total Akt showed no change.
To further investigate the molecular mechanism underlying the SLC6A14-regulated cell invasion in CRC, we detected matrix remodeling protein expression in HCT116 and Caco2 cells and found that MMP2, MMP9, and MT1-MMP were downregulated by treated with SLC6A14-siRNA or α-MT (Fig. 6A and C).
Pharmacological blockade of SLC6A14 in vivo inhibits xenograft tumor growth
We next assessed the role of SLC6A14 in a CRC xenograft mouse model. HCT116 cells were subcutaneously injected into nude mice (n = 6), and the effect of α-MT on tumor proliferation was evaluated. As shown in Fig. 7A, B and C, we found that α-MT dramatically inhibited CRC tumor growth in these mice compared to the control group. Immunohistochemical staining confirmed that the tumors from the α-MT-treated mice had much lower SLC6A14 and mTOR protein expression (Fig. 7D). Taken these data together, it suggests that pharmacological blockade of SLC6A14 with α-MT effectively suppresses the in vivo growth of CRC.
As rapid proliferating of cancer cells needs a great number of nutrients to support increased biosynthesis and thus many different nutrient transporters are overexpressed on the cell surface, so metabolic reprogramming is recognized as a new hallmark of cancer cells recently [31,32,33]. Elevated expression of nutrient transporter proteins in malignant cancers and low expression in normal tissues are ideal targets for selective anticancer therapies [34,35,36]. SLC6A14 has been shown to be such a cancer-specific amino acid transporter: it is highly expressed in estrogen receptor-positive (ER+) breast cancers and pancreatic cancer, but low in normal tissues . Moreover, SLC6A14 knockout mice have no obvious phenotype and show normal fertility and breast development . α-MT, a small-molecule inhibitor targeting SLC6A14, has been successfully employed to block the function of SLC6A14 in a breast cancer xenograft model. Furthermore, α-MT can inhibit tumor cell proliferation both in vitro and in vivo only in SLC6A14-positive breast cancer lines, but not in SLC6A14-negative breast cancer cell lines . These findings strongly indicate that whether SLC6A14 can be a potential tumor target depends on its expression in this tumor.
Our study demonstrated that the mRNA and protein levels of SLC6A14 were upregulated in CRC tissues, as determined by qPCR and immunohistochemistry arrays, in accordance with the results of the TCGA database. In spite of the expression of some amino acid transporters in our study did not agree with the results of TCGA, such as SLC7A4 and SLC7A6. This may be due to the limited sample size used in our study. A large sample with multi-center prospective cohort studies should be performed to confirm these results. Although the upregulation of SLC6A14 in CRC has been well demonstrated by our data and literature [24, 25], we noticed the low expression level of SLC6A14 in SW480 cells, compared to other CRC cell lines including HT29, HCT116, SW620 and Caco2. This was also reported by Karunakaran S, et al.  This is mainly due to the higher differentiation of SW480 cells. We have demonstrated that the expression levels of SLC6A14 were closely related to the tumor cells differentiation: the higher the expression of SLC6A14 was, the poorer the differentiation of the tumor was. In CRC, SLC6A14 shows high expression in poorly-differentiated HCT116 cells and undifferentiated Caco-2 cells, while low in differentiated HT29 and SW480 cells. When Caco2 cells were differentiated to the small intestinal epithelium in vitro, SLC6A14 lost the expression . However, we cultured Caco2 cells in the undifferentiated medium in the current study, showing maintenance of the high level of SLC6A14. Moreover, the relationship between SLC6A14 and clinicopathological variables was further found that the higher the clinical stage was, the higher the expression level of SLC6A14 in CRC was. Subsequently, we provided evidence that knockdown of SLC6A14 expression or treatment with α-MT reduced CRC cell proliferation and migration in vitro through restricting amino acids uptake and inhibited xenograft tumor growth in vivo. It has been well demonstrated that among the 20 amino acids, 18 of them can be transported by SLC6A14 except for L-glutamate and L-aspartate. In addition, nonessential amino acids including L-histidine, L-ornithine, and L-citrulline can be synthesized endogenously by mammalian cells. As a result, these five amino acids in the culture supernatant may not be transported by SLC6A14 or not be required by HCT116 cells. This may explain the reason why histidine, ornithine, citrulline, and aspartic acid in the cell culture supernatant did not show influence by silencing of SLC6A14. Although we observed the increase of glutamate in the culture supernatant following SLC6A14-siRNA treatment or pharmacological blockade of SLC6A14 with α-MT, the mechanism remains to be determined. Taken together, these results highlight that SLC6A14 could be an effective molecular target for the treatment of CRC.
To date, the expression of SLC6A14 is upregulated in estrogen receptor-positive breast cancer, cervical cancer, pancreatic cancer, and colorectal cancer [19,20,21, 24, 25]. Furthermore, Sikder MOF et al.  demonstrated that the tumor-associated up-regulation of SLC6A14 was likely to be driven by Wnt signaling by activating the downstream mediator TCF4/β-catenin. Mao et al. found that SLC6A14 promoted proliferation and metastasis of CRC via enhancing the JAK2/STAT3 pathway . However, little is known about SLC6A14 being involved in downstream signaling pathways in CRC proliferation. In our study, we not only detected the overexpression of SLC6A14 in CRC but also demonstrated that SLC6A14 affected the mTOR signaling pathway in CRC cells. Knockdown of SLC6A14 with siRNA or blockade with α-MT inhibited the activity of mTOR, phosphorylated mTOR (Ser2448), GβL, and Raptor, which constituted rapamycin complex 1 (mTORC1). Moreover, knockdown of SLC6A14 with siRNA or blockade with α-MT decreased phosphorylated p70S6 and S6, but increased phosphorylated 4E-BP1. As we all know, p70S6, S6 and 4E-BP1 are the downstream effectors of mTOR: p70S6 and S6 phosphorylation stimulate protein synthesis; phosphorylated 4E-BP1 inhibits protein synthesis by binding to EIF4E. And mTOR is usually regulated by PI3K/Akt signaling, so Akt is the upstream molecule of mTOR. As shown in our study, p-Akt (Ser 473) was downregulated in the cells treated either with SLC6A14-siRNA or α-MT blockade, while total Akt was not changed. Taken these data together, it suggested that SLC6A14 regulated the activity of Akt-mTOR signaling molecules, which is a key pathway in the control of tumor cell proliferation and mobility [39,40,41]. This observation is in accordance with the fact that SLC6A14 is sufficient for the active import of almost all of the amino acids from the extracellular medium, among which L-glutamine and L-leucine are key activators of the mTORC1 signaling pathway [42, 43]. It is also reported that SLC38A9, a key component of a lysosomal membrane complex, interacts with the Rag GTPases and Ragulator in an amino acid-sensitive fashion, and activates mTORC1 by amino acids, particularly arginine . Thus, through SLC38A9, arginine serves as a lysosomal messenger that couples mTORC1 activation to the release from lysosomes of the essential amino acids needed to drive cell growth .
By application of 482 tissue samples of CRC and three additional CRC cell lines HCT116, Caco2 and SW480, our current study not only further confirmed the findings by Mao et al. and Sikder et al. but also demonstrated a novel regulatory mechanism through which Akt-mTOR signaling mediated the function of SLC6A14 in CRC. In combination with the findings by our study and literature, the molecular mechanisms for SLC6A14 in regulating CRC through Wnt signaling, Akt-mTOR signaling, and JAK2/STAT3 signaling were determined.
In addition, LC-MS/MS analysis was applied in our study to determine concentrations of 20 amino acids in the supernatant of HCT116 cells with or without expression of SLC6A14. As a result, we are the first to find that 16 of the 20 amino acids were increased in the supernate of HCT116 cells after silencing of SLC6A14 with siRNA or blockade with α-MT, demonstrating an important role of SLC6A14 in the regulation of amino acid uptake in CRC cells, which are essential for cancer cell proliferation.
Pharmacological blockade of these nutrient transporters might offer a novel strategy in cancer therapy: “starve the tumor cells to death” , so a small-molecule inhibitor with minimal toxicity targeting SLC6A14 is worth seeking. α-MT was identified as a blocker for SLC6A14, which caused 50% blockage of SLC6A14 transport function when the concentrations of all these 18 amino acids were up to ∼250 μM in vivo conditions. α-MT can suppress colony-forming ability and cell cycle arrest in SLC6A14-positive tumor cells, whereas SLC6A14-negative cell lines are not affected . α-MT has been successfully applied to SLC6A14-positive breast cancer xenograft models and significantly suppresses tumor growth . Our results showed that α-MT inhibited CRC cell lines (HCT116 and Caco2) proliferation, promoted cell apoptosis, reduced migration in vitro as expected, and suppressed tumor growth in a nude mouse CRC model. However, the effect of α-MT on SW480, which was low-expressed SLC6A14, did not show any significant change of cell proliferation and cell apoptosis, compared to controls when treated with either SLC6A14-siRNA or α-MT blockade. These results show that α-MT may lead to the deprivation of amino acids in cells dependent on transporters. However, whether α-MT can be a candidate for novel approaches to CRC therapy requires further study on the role of SLC6A14 in a variety of cancers. Moreover, although the single use of α-MT is encouraging, it is more important to assess whether the combination of drugs will lead to greater inhibition and suppress the development of drug resistance.
In conclusion, our experiments indicated that SLC6A14 was upregulated and could activate the Akt-mTOR signaling pathway, thereby promoting the tumor progression of CRC. Blockade of SLC6A14 with α-MT reduced CRC cell growth in vitro and in vivo. These findings highlight the clinical and therapeutic utility of SLC6A14 to target the constitutive anabolism of CRC for treatment.
Availability of data and materials
The datasets generated during the current study are not publicly available but de-identified and anonymized information is potentially available on reasonable request from the corresponding author (Ying Lu).
Cell signaling technology
Fetal calf serum
G protein beta subunit like protein
Liquid chromatograph-mass spectrometer
Mammalian target of rapamycin
- real-time PCR:
Real-time polymerase chain reaction
Solute carrier family 6 member 14
The cancer genome atlas
Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. Colorectal cancer. Lancet. 2019;394(10207):1467–80.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.
Piawah S, Venook AP. Targeted therapy for colorectal cancer metastases: a review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer. Cancer. 2019;125(23):4139–47.
Russo M, Crisafulli G, Sogari A, Reilly NM, Arena S, Lamba S, et al. Adaptive mutability of colorectal cancers in response to targeted therapies. Science. 2019;366(6472):1473–80.
Barberini L, Restivo A, Noto A, Deidda S, Fattuoni C, Fanos V, et al. A gas chromatography-mass spectrometry (GC-MS) metabolomic approach in human colorectal cancer (CRC): the emerging role of monosaccharides and amino acids. Ann Transl Med. 2019;7(23):727.
Zhang L, Sui CG, Yang WH, Luo Q. Amino acid transporters: emerging roles in drug delivery for tumor-targeting therapy. Asian J Pharm Sci. 2020;15(2):192–206.
Lin L, Yee SW, Kim RB, Giacomini KM. SLC transporters as therapeutic targets: emerging opportunities. Nat Rev Drug Discov. 2015;14(8):543–60.
Cha YJ, Kim ES, Koo JS. Amino acid transporters and glutamine metabolism in breast Cancer. Int J Mol Sci. 2018;19(3):907.
Lewerenz J, Hewett SJ, Huang Y, Lambros M, Gout PW, Kalivas PW, et al. The cystine/glutamate antiporter system X(c)(−) in health and disease: from molecular mechanisms to novel therapeutic opportunities. Antioxid Redox Signal. 2013;18(5):522–55.
Van Geldermalsen M, Wang Q, Nagarajah R, Marshall AD, Thoeng A, Gao D, et al. ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast Cancer. Oncogene. 2016;35(24):3201–8.
Liu Y, Zhao T, Li Z, Wang L, Yuan S, Sun L. The role of ASCT2 in cancer: a review. Eur J Pharmacol. 2018;837:81–7.
Häfliger P, Charles RP. The L-type amino acid transporter LAT1-an emerging target in Cancer. Int J Mol Sci. 2019;20(10):2428.
Koppula P, Zhang Y, Zhuang L, Gan B. Amino acid transporter SLC7A11/xCT at the crossroads of regulating redox homeostasis and nutrient dependency of cancer. Cancer Commun (Lond). 2018;38(1):12.
Dai L, Cao Y, Chen Y, Parsons C, Qin Z. Targeting xCT, a cystine-glutamate transporter induces apoptosis and tumor regression for KSHV/HIV-associated lymphoma. J Hematol Oncol. 2014;7:30.
Jiang L, Kon N, Li TY, Wang SJ, Su T, Hibshoosh H, et al. Ferroptosis as a p53-mediated activity during tumour suppression. Nature. 2015;520(7545):57–62.
Lu Y, Wang WM, Wang JC, Yang C, Mao H, Fu X, et al. Overexpression of arginine transporter CAT-1 is associated with accumulation of L-arginine and cell growth in human colorectal Cancer tissue. PLoS One. 2013;8(9):e73866.
Nakanishi T, Hatanaka T, Huang W, Prasad PD, Leibach FH, Ganapathy ME, et al. Na+− and Cl--coupled active transport of carnitine by the amino acid transporter ATB (0,+) from mouse colon expressed in HRPE cells and Xenopus oocytes. J Physiol. 2001;532(Pt 2):297–304.
Sikder MOF, Yang S, Ganapathy V, Bhutia YD. The Na +/Cl --Coupled, Broad-Specific, Amino Acid Transporter SLC6A14 (ATB 0,+): Emerging Roles in Multiple Diseases and Therapeutic Potential for Treatment and Diagnosis. AAPS J. 2017;20(1):12.
Royse KE, Zhi D, Conner MG, Clodfelder-Miller B, Srinivasasainagendra V, Vaughan LK, et al. Differential gene expression landscape of co-existing cervical pre-Cancer lesions using RNA-seq. Front Oncol. 2014;4:339.
Coothankandaswamy V, Cao S, Xu Y, Prasad PD, Singh PK, Reynolds CP, et al. Amino acid transporter SLC6A14 is a novel and effective drug target for pancreatic cancer. Br J Pharmacol. 2016;173(23):3292–306.
Karunakaran S, Ramachandran S, Coothankandaswamy V, Elangovan S, Babu E, Periyasamy-Thandavan S, et al. SLC6A14 (ATB0,+) protein, a highly concentrative and broad specific amino acid transporter, is a novel and effective drug target for treatment of estrogen receptor-positive breast cancer. J Biol Chem. 2011;286(36):31830–8.
Babu E, Bhutia YD, Ramachandran S, Gnanaprakasam JP, Prasad PD, Thangaraju M, et al. Deletion of the amino acid transporter Slc6a14 suppresses tumour growth in spontaneous mouse models of breast Cancer. Biochem J. 2015;469(1):17–23.
McCracken AN, Edinger AL. Targeting Cancer metabolism at the plasma membrane by limiting amino acid access through SLC6A14. Biochem J. 2015;470(3):e17–9.
Gupta N, Miyauchi S, Martindale RG, Herdman AV, Podolsky R, Miyake K, et al. Upregulation of the amino acid transporter ATB0,+ (SLC6A14) in colorectal cancer and metastasis in humans. Biochim Biophys Acta. 2005;1741(1–2):215–23.
Mao H, Sheng J, Jia J, Wang C, Zhang S, Li H, et al. Aberrant SLC6A14 expression promotes proliferation and metastasis of colorectal Cancer via enhancing the JAK2/STAT3 pathway. Onco Targets Ther. 2021;14:379–92.
Yeo W, Chan SL, Mo FK, Chu CM, Hui JW, Tong JH, et al. Phase I/II study of temsirolimus for patients with unresectable hepatocellular carcinoma (HCC)- a correlative study to explore potential biomarkers for response. BMC Cancer. 2015;15:395.
Sikder MOF, Sivaprakasam S, Brown TP, Thangaraju M, Bhutia YD, Ganapathy V. SLC6A14, a Na+/Cl--coupled amino acid transporter, functions as a tumor promoter in colon and is a target for Wnt signaling. Biochem J. 2020;477(8):1409–25.
Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 2017;19(8):649–58.
Kim DH, Sarbassov DD, Ali SM, Latek RR, Guntur KV, Erdjument-Bromage H, et al. GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Mol Cell. 2003;11(4):895–904.
Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol. 2004;14(14):1296–302.
Boroughs LK, DeBerardinis RJ. Metabolic pathways promoting cancer cell survival and growth. Nat Cell Biol. 2015;17(4):351–9.
Weyandt JD, Thompson CB, Giaccia AJ, Rathmell WK. Metabolic Alterations in Cancer and Their Potential as Therapeutic Targets. Am Soc Clin Oncol Educ Book. 2017;37:825–32.
Ortmayr K, Dubuis S, Zampieri M. Metabolic profiling of cancer cells reveals genome-wide crosstalk between transcriptional regulators and metabolism. Nat Commun. 2019;10(1):1841.
Saito Y, Li L, Coyaud E, Luna A, Sander C, Raught B, et al. LLGL2 rescues nutrient stress by promoting leucine uptake in ER(+) breast cancer. Nature. 2019;569(7755):275–9.
Zhang Y, Zhang Y, Sun K, Meng Z, Chen L. The SLC transporter in nutrient and metabolic sensing, regulation, and drug development. J Mol Cell Biol 2019;11(1):1–13.
Anderson CM, Howard A, Walters JR, Ganapathy V, Thwaites DT. Taurine uptake across the human intestinal brush-border membrane is via two transporters: H+-coupled PAT1 (SLC36A1) and Na+− and cl(−)-dependent TauT (SLC6A6). J Physiol. 2009;587(Pt 4):731–44.
Karunakaran S, Umapathy NS, Thangaraju M, Hatanaka T, Itagaki S, Munn DH, et al. Interaction of tryptophan derivatives with SLC6A14 (ATB0,+) reveals the potential of the transporter as a drug target for cancer chemotherapy. Biochem J. 2008;414(3):343–55.
Wang Q, Holst J. L-type amino acid transport and cancer: targeting the mTORC1 pathway to inhibit neoplasia. Am J Cancer Res. 2015;5(4):1281–94.
Tian T, Li X, Zhang J. mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy. Int J Mol Sci. 2019;20(3):755.
Mossmann D, Park S, Hall MN. mTOR signalling and cellular metabolism are mutual determinants in cancer. Nat Rev Cancer. 2018;18(12):744–57.
Bernfeld E, Menon D, Vaghela V, Zerin I, Faruque P, Frias MA, et al. Phospholipase D-dependent mTOR complex 1 (mTORC1) activation by glutamine. J Biol Chem. 2018;293(42):16390–401.
Feng M, Xiong G, Cao Z, Yang G, Zheng S, Qiu J, et al. LAT2 regulates glutamine-dependent mTOR activation to promote glycolysis and chemoresistance in pancreatic cancer. J Exp Clin Cancer Res. 2018;37(1):274.
Wolfson RL, Chantranupong L, Saxton RA, Shen K, Scaria SM, Cantor JR, et al. Sestrin2 is a leucine sensor for the mTORC1 pathway. Science. 2016;351(6268):43–8.
Wang S, Tsun ZY, Wolfson RL, Shen K, Wyant GA, Plovanich ME, et al. Metabolism. Lysosomal amino acid transporter SLC38A9 signals arginine sufficiency to mTORC1. Science. 2015;347(6218):188–94.
Wyant GA, Abu-Remaileh M, Wolfson RL, Chen WW, Freinkman E, Danai LV, et al. mTORC1 activator SLC38A9 is required to efflux essential amino acids from lysosomes and use protein as a nutrient. Cell. 2017;171(3):642–54.
Cormerais Y, Vucetic M, Pouysségur J. Targeting amino acids transporters (SLCs) to starve cancer cells to death. Biochem Biophys Res Commun. 2019;520(4):691–3.
We would like to thank Prof. Zuoren Yu (Research Center for Translational Medicine, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China) for advice and help.
This work was supported by grants from the Science and Technology Development Foundation of Pudong New District, Shanghai (No. PKJ2016-Y63 to Y.L.), the National Natural Sciences Foundation of China (No. 82001725 to Y.L. and 81972183 to Z.X.). the Natural Science Foundation of Jiangxi Province (No. 20181BAB205033 to Y.L.)
Ethics approval and consent to participate
This study was approved by the Ethics Committee of Shanghai East Hospital of Tongji University, and written informed consent was obtained from each patient. The study was carried out in compliance with the ARRIVE guidelines. All methods were carried out in accordance with relevant guidelines and regulations. All participants were 16 years or older at the time of the study.
Consent for publication
The authors have declared that no competing interest exists.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Lu, Y., Jiang, Z., Wang, K. et al. Blockade of the amino acid transporter SLC6A14 suppresses tumor growth in colorectal Cancer. BMC Cancer 22, 833 (2022). https://doi.org/10.1186/s12885-022-09935-0
- Colorectal cancer
- Amino acid transporter